Phibro Animal Health Corporation (PAHC) Q4 2025 Earnings Conference Call Transcript

Phibro Animal Health Corporation (PAHC) reported a strong close to fiscal year 2025, with consolidated sales up 27% to $1.296 billion and adjusted EBITDA up 65%, largely fueled by the successful integration of the Zoetis Medicated Feed Additive business and robust growth in its Animal Health segment. The company issued robust fiscal year 2026 guidance, forecasting net sales between $1.425 billion and $1.475 billion and adjusted EBITDA of $225 million to $235 million. This outlook signals confidence in sustained momentum from the Zoetis acquisition and its 'Phibro Forward' strategic initiatives, highlighting PAHC's effective execution of its growth strategy leveraging both inorganic and organic drivers.

Analysis

Phibro Animal Health Corporation (PAHC) reported a standout finish to fiscal year 2025, driven by the successful integration of the Zoetis Medicated Feed Additive (MFA) business. Consolidated net sales rose 39% in Q4 and 27% for the full year to $1.296 billion, while full-year adjusted EBITDA surged 65%. The primary catalyst was the Animal Health segment, where sales grew 36% for the year, bolstered by an $208.2 million contribution from the newly acquired Zoetis MFA portfolio over eight months. Importantly, the legacy Animal Health business also demonstrated strength, growing 7% and outpacing the underlying industry, with Nutritional Specialties and Vaccines delivering robust growth of 9% and 13% respectively. The company's strategic initiative, 'Phibro Forward', is already contributing to margin expansion and is cited as a key driver for future growth.

The forward-looking guidance for fiscal year 2026 underscores management's confidence, projecting net sales growth of 10-14% and adjusted EBITDA growth of 22-28%. This outlook is underpinned by the full 12-month contribution from the Zoetis acquisition, which is expected to account for at least half of the projected $40-50 million in incremental EBITDA, with the remainder coming from the legacy business and the 'Phibro Forward' program. The company maintains a stable financial position, with net leverage at 2.8x and consistent dividend payments, even after the significant acquisition.

Key Decisions for Investors

• Given the robust FY2026 guidance projecting 22-28% adjusted EBITDA growth, investors should assess whether PAHC's current valuation fully reflects the earnings power from the annualized Zoetis acquisition and the margin benefits from the 'Phibro Forward' initiative.
• Monitor the performance of the legacy business, particularly the high-growth Nutritional Specialties and Vaccines segments, as their continued momentum is crucial for sustaining organic growth alongside the inorganic contribution from Zoetis.
• Investors should track the successful completion of the Zoetis integration, expected by calendar Q4, and look for early evidence of cross-selling synergies and market expansion which could provide upside to current forecasts.
• Key risks to monitor include the impact of higher interest expense on the 2.8x net leverage, a potential slowdown in the strong growth of the legacy portfolio, and any adverse changes to international tariffs not currently factored into guidance.